The pharmacokinetics of atazanavir/ritonavir 200/100 OD versus 300/100 mg OD in combination with 2 NRTIs [nucleoside reverse transcriptase inhibitors] in HIV pre-treated patients.
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2010
At a glance
- Drugs Atazanavir; Nucleoside reverse transcriptase inhibitors; Ritonavir
- Indications HIV infections
- Focus Pharmacokinetics
- 04 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 10 Jan 2007 Status change